Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/bloodadvances.2024015712 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Blood Adv
February 2025
University of Chicago, Chicago, Illinois, United States.
Predictive Models for Long Term Survival of AML Patients Treated with Venetoclax and Azacitidine or 7+3 Based on Post Treatment Events and Responses: Retrospective Cohort Study.
JMIR Cancer
August 2024
Department of Medicine, University of Colorado Anschutz, Aurora, CO, United States.
Background: The treatment of acute myeloid leukemia (AML) in older or unfit patients typically involves a regimen of venetoclax plus azacitidine (ven/aza). Toxicity and treatment responses are highly variable following treatment initiation and clinical decision-making continually evolves in response to these as treatment progresses. To improve clinical decision support (CDS) following treatment initiation, predictive models based on evolving and dynamic toxicities, disease responses, and other features should be developed.
View Article and Find Full Text PDFSFXN3 is a Prognostic Marker and Promotes the Growth of Acute Myeloid Leukemia.
Cell Biochem Biophys
September 2024
Department of Hematology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230000, China.
Acute myeloid leukemia (AML) is a heterogeneous disease with rapid progression and frequent mutations. Sideroflexin3 (SFXN3) has been shown to be involved in various neurodegenerative diseases. However, the role of SFXN3 in AML remains unclear.
View Article and Find Full Text PDFIdentification and validation of a prognostic risk-scoring model for AML based on mG-associated gene clustering.
Front Oncol
January 2024
Department of Hematology, Central People's Hospital of Zhanjiang, Zhanjiang, China.
Background: Acute myeloid leukemia (AML) patients still suffer from poor 5-year survival and relapse after remission. A better prognostic assessment tool is urgently needed. New evidence demonstrates that 7-methylguanosine (m7G) methylation modifications play an important role in AML, however, the exact role of m7G-related genes in the prognosis of AML remains unclear.
View Article and Find Full Text PDFEstablishment and validation of a prognostic immune-related lncRNA risk model for acute myeloid leukemia.
Transl Cancer Res
December 2023
Department of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
Background: Acute myeloid leukemia (AML) is a cancer arising in the bone marrow and is the most common type of adult leukemia. AML has a poor prognosis, and currently, its prognosis evaluation does not include immune status assessment. This study established an immune-related long non-coding RNA (lncRNA) prognostic risk model for AML based on immune lncRNAs screening.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!